Innate Pharma (IPHA) Assets Average (2018 - 2025)

Innate Pharma has reported Assets Average for 7 years, with the latest figure at $89.1 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average fell 36.77% year-over-year to $89.1 million; the trailing twelve-month figure through Dec 2025 stood at $89.1 million (down 36.77% YoY), and the FY2025 full-year result was $95.8 million, down 37.6% from the prior year.
• Assets Average for Q4 2025 stood at $89.1 million, down from $111.9 million in the prior quarter.
• The five-year high for Assets Average was $343.6 million in Q2 2021, with the low at $89.1 million in Q4 2025.
• Historically, Assets Average has averaged $215.0 million across 5 years, with a median of $208.5 million in 2023.
• Annual changes were most pronounced in 2021 — Assets Average slumped 99.81% — and 2022, when it decreased 11.92%.
• Innate Pharma's Assets Average stood at $313.3 million in 2021, then decreased by 18.4% to $255.7 million in 2022, then decreased by 20.74% to $202.6 million in 2023, then sank by 30.46% to $140.9 million in 2024, then plunged by 36.77% to $89.1 million in 2025.
• The last three Assets Average figures came in at $89.1 million (Q4 2025), $111.9 million (Q2 2025), and $140.9 million (Q4 2024), per Business Quant data.